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Abstract
Background Sarcopenia, the age-related decline in skeletal
muscle mass and function, is a relatively poorly understood
process which may play an important role in the incidence
of physical disability and falls in older adults. Evidence
demonstrates that both genetic and environmental factors
contribute to increased susceptibility for sarcopenia devel-
opment, yet some of these factors may represent unavoid-
able consequences of ageing.
Methods A review of literature, generally from epidemio-
logical research, was performed to examine the influence
that potentially modifiable lifestyle factors (general physi-
cal activity, dietary nutrient intake and sun exposure), as
well as chronic disease and medication use, may have on
sarcopenia progression.
Results The review demonstrated that while physical activity,
nutrient intake and sun exposure often decline during ageing,
each may have important but differing benefits for the
prevention of muscle mass and functional declines in older
adults. Conversely, age-related increases in the prevalence of
chronic diseases and the subsequent prescription of pharma-
cotherapy may exacerbate sarcopenia progression.
Conclusions The prevalence of poor physical activity, diet
and sun exposure, as well as chronic disease and medica-
tion use, within older adult populations may be modifiable
through simple lifestyle and health care interventions. As
such, these factors may represent the most effective targets




Irwin Rosenberg first noted that age-related declines in
muscle mass are dramatic and have wide-ranging health
outcomes [1], and proposed the descriptor ‘sarcopenia’ in
1988 [2]. In subsequent literature, the term has evolved to
additionally describe age-related declines in muscle func-
tion [3], and recent recommendations for clinical definitions
of sarcopenia promote combined measurement protocols,
including measures of low walking speed [4–6]. However,
an internationally accepted consensus definition of sarco-
penia does not presently exist, in part due to conjecture
regarding whether it is a disease state or process of
normative ageing [7]. The present review analyses sarco-
penia as a continuous and ubiquitous process impacting
both skeletal muscle mass and function.
Symptoms of sarcopenia may develop as early as the
fourth decade of life [8], but observed rates of progression
vary by population and assessment techniques. Most
longitudinal studies analyse changes in muscle strength
rather than muscle mass, and results indicate that decreases
in knee and elbow strength are in the range of 1–4% per
year in older adult populations [9–12], but declines may be
significantly greater for men than women [13], indicating
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DOI 10.1007/s13539-011-0036-4sex-specific differences. Hand grip strength may decline at
a faster rate in UK [14] than in US [15] older adults, and
decreases in strength may also vary between muscle groups
[16].
Prospective changes in thigh cross-sectional area (CSA)
assessed by computed tomography reveal decreases of only
0.5–1.0% per year [10, 11]. Indeed, the Health, Aging, and
Body Composition (Health ABC) study demonstrated that
annual decreases in muscle strength are two- to fivefold
greater than decreases in muscle CSA [12], and muscle
mass changes explain as little as 5% of the variation in
change in muscle strength in older adults [13, 17]. Changes
in ‘muscle quality’, the amount of force produced per unit
of muscle mass, may therefore explain much of the strength
loss during ageing [18] and are possibly attributable to age-
related neuromuscular changes, including reductions in
muscle fibre size, number and contractility, as well as
skeletal muscle fat infiltration [19]. Muscle quality
decreased by 5–9% in 3 years in US adults aged 70–
79 years [17], suggesting it may be a useful indicator of
sarcopenia progression. Neuromuscular changes along
with changes in body fat, systemic low-level inflamma-
tion, oxidative stress, protein metabolism, and endocrine
activity contribute to sarcopenia, but may be a result of
normative ageing and are therefore beyond the scope of
this review. This review instead focuses on common
lifestyle behaviours, chronic disease and medication use,
all of which may be modifiable.
2 Lifestyle determinants of sarcopenia
The aetiology of sarcopenia is multifactorial, and its
progression is generally attributed to age-related changes
in skeletal muscle: an increased withdrawal of, or resistance
to anabolic factors, and a concurrent increase in catabolic
factors [20]. However, the heritability of muscle mass and
strength may be as high as 50–60% [21–25], indicating that
the development of sarcopenia is under significant genetic
control. Indeed, a number of genes have already been
identified as potential mediators of sarcopenia [26].
Additionally, early life influences may determine sarco-
penia progression in later life. In the Hertfordshire Cohort
Study (HCS), including nearly 3,000 UK older adults, birth
weight and weight at 1 year positively predicted fat-free
mass [27], muscle CSA [28], and hand grip strength [29],
and lower infant growth was associated with a history of
falls in men [30]. Birth weight was also positively
associated with grip strength after adjustment for childhood
and adult body size in a cohort of adults born in the UK in
1946 [31], and standing balance and chair rise ability was
positively predicted by weight gain before the age of
7 years in men [32]. Low birth weight has also been
associated with low lean mass and hand grip strength in
population-based studies of European older adults [33, 34],
and early life experience of famine was associated with
slower walking speed, shorter stride length, and recurrent
falls in older adults in Hong Kong [35].
Life course studies therefore suggest that a modest but
significant proportion of the origins of sarcopenia may be
found in the prenatal and post-natal environment, and that
declines in skeletal muscle mass and function during older
age may be related to lifestyle behaviours during early
development. It is likely that lifestyle choices during later
life are also predictive of sarcopenia progression.
2.1 Physical activity
The effectiveness of resistance training interventions in
reversing skeletal muscle mass and function declines
indicative of sarcopenia progression has been demonstrated
unequivocally [36]. However, general physical activity
levels may be a more appropriate target from a public
health standpoint, and it would appear logical that even
general physical activity could hold benefits for skeletal
muscle given that muscle contractions are associated with
anabolic effects including increases in anti-inflammatory
and antioxidative activity [37].
Studies have examined associations between general
physical activity, muscle mass and strength in older adults,
but its potential impact on sarcopenia prevention is unclear.
A cross-sectional study of older French women revealed a
positive association between self-reported habitual physical
activity, leisure-time physical activity and maximal anaer-
obic power of the quadriceps [38], but a study of Dutch
older adults reported no association between self-reported
leisure-time physical activity and hand grip strength [39].
The New Mexico Aging Process study revealed positive
associations between self-reported physical activity and
muscle mass for older men and women [40] and relative
appendicular lean mass (ALM) was greater with increased
intensity of work activities, and in those who reported
regular leisure-time exercise [41].
However, self-reported physical activity was not associ-
ated with ALM assessed by dual-energy X-ray absorptiom-
etry (DXA) in over 300 older adults [42], and the US
National Health and Nutrition Examination and the New
Mexico Elder Health Surveys have provided conflicting
findings regarding whether low self-reported physical
activity is associated with a greater likelihood of being
sarcopenic [43, 44]. Differences in cross-sectional associa-
tions are likely to be explained in some part by the use of
different instruments for assessing self-reported physical
activity, all of which have a substantial measurement error.
Prospective studies of associations in older adults between
self-reported physical activity, muscle mass, and function
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attenuated decline in thigh girth, but not knee extensor or
flexor strength, in older adults over nearly 10 years [13,
45]. Physical disability has been associated with low self-
reported physical activity in other prospective population-
based studies [46].
Few studies of sarcopenia have objectively analysed
physical activity levels. Ambulatory activity (AA) is the
most popular form of leisure-time physical activity for older
adults [47] and may be assessed by several objective
measurement tools [48]. A significant association between
strength of the triceps surae and total daily AAwas assessed
by pedometer in older men, but not women [49].
Pedometer-determined AA has been associated with lower
adiposity in cross-sectional studies of older adults [50–52],
and AA may indirectly prevent declines in skeletal muscle
quality and function by reducing body fat levels [53].
The Tasmanian Older Adult Cohort (TASOAC) study
was a prospective, population-based study of 1,100
community-dwelling older adults (mean age, 62 years).
Baseline analyses revealed that pedometer-determined AA
was negatively associated with total body fat and trunk fat
mass in both sexes, and positively associated with leg
strength and muscle quality in women only [54]. However,
prospective analyses over 2.6 years demonstrated that
habitual AA predicted declines in body fat for men,
increased leg strength and muscle quality in women, and
increased leg lean mass in both sexes [55]. These findings
indicate that general physical activity may be of benefit in
the prevention of sarcopenia, particularly through mainte-
nance of desirable body composition, and there does not
appear to be a threshold for this association.
2.2 Diet
In healthy adults, muscle constitutes over half of total body
protein, but this decreases with age [56] due to greater rates
of protein breakdown than synthesis. Daily energy intake
declines by as much as 5,000 kJ in men and 3,500 kJ in
women in their 80s, with substantial declines in intakes of
nutrients, including protein [57]. Decreased dietary intakes
of protein, as well as other nutrients, may contribute to
sarcopenia progression.
Serum albumin is positively associated with DXA-
assessed skeletal muscle mass in older adults [58], and in
an Australian population-based study, participants who
failed to meet recommendations for protein intake demon-
strated significantly lower mean ALM [59]. However,
several cross-sectional studies examining protein intake in
older adults have reported no associations with muscle
mass or strength [40, 60, 61]. Longitudinal studies have
provided more support for the notion of a protective effect
of dietary protein for sarcopenia; gains in mid-arm muscle
area were associated with higher self-reported baseline
protein intake in a 4-year study of Chinese older adults
[62], and those in the highest quintile for protein intake in
the Health ABC Study had around 40% less decline in lean
mass over 3 years than those in the lowest quintile [63].
Similarly, baseline protein intake was positively correlated
with whole body lean mass, ALM and upper arm muscle
area 5 years later in a study of Australian older women
[64], and was a positive predictor of change in ALM over
3 years in Australian older men and women [59].
Literature examining the influence of non-protein dietary
components on sarcopenia is less common. Carotenoids
may be protective against oxidative stress, and subsequent-
ly, sarcopenia [65]. In Canadian adults aged 60–75 years,
odds for sarcopenia were greater in those who reported
failing to meet recommended dietary allowances for the
antioxidants selenium and vitamins A, C and E [66], and in
the HCS a positive association was observed for hand grip
strength with β-carotene, selenium and vitamin C [67]. In
the Women’s Health and Aging Study (WHAS) of nearly
700 community-dwelling women aged 70–79 years, high
plasma carotenoid and α-tocopherol (a form of vitamin E)
status were associated with reduced odds for low muscle
strength [68] and frailty [69]. Over 3 years in this study, low
plasma carotenoid status at baseline predicted development
of frailty [70], walking disability [71, 72] and ADL
disability [73]. Several examinations of carotenoid status
have also been conducted within the InCHIANTI study.
Objectively measured plasma α-tocopherol and γ-
tocopherol, and self-reported intakes of vitamin C and β-
carotene, were positively associated with knee extension
strength and physical performance score [74], and low
plasma selenium intake was associated with higher risk of
poor muscle strength [75]. A 6-year follow-up revealed that
a higher baseline carotenoid status predicted a reduced risk
of developing poor hand grip, knee and hip strength [76],
and walking disability [77]. The TASOAC study, however,
revealed no associations between vitamin C and E and
prospective changes in ALM over 3 years in older adults
although zinc, which may have antioxidant properties, was
a positive predictor of change in ALM even after
adjustment for protein intake [59].
Diets high in fruit and vegetables may also be beneficial
due to increased potassium intake, which may reduce
metabolic acidosis. Urinary potassium and potassium
intakes have been positively associated with lean mass
and muscle strength in older adults [78, 79] but not
prospective changes in lean mass over 3 years [59, 78].
Magnesium may also be preventative of skeletal muscle
declines by contributing to muscle adenosine triphosphate
and cell structure. Serum magnesium concentrations were
positively associated with grip strength, lower limb muscle
power and lower limb extension strength in the InCHIANTI
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[79] and was also a positive predictor of change in ALM in
a 3-year prospective study of older adults [59]. Evidence
therefore suggests that several dietary components may be
involved in sarcopenia progression.
2.3 Vitamin D
Vitamin D is a secosteroid hormone produced following
ultraviolet B light exposure and also obtained in small
amounts from some foods [81]. Vitamin D insufficiency
and deficiency may be prevalent in older adults and
particularly amongst those who live at higher latitudes
[82]. Nuclear 1, 25 vitamin D receptors (VDRs) located in
skeletal muscle may bind 1,25-dihydroxyvitamin D
(1,25OHD3; the active form of vitamin D) and promote
protein synthesis, and the apparent decrease in VDRs
within the muscle during ageing may explain some of the
age-related decline in protein synthesis [83]. Indeed, VDR
polymorphisms have been associated with low fat-free mass
in older men and muscle strength in older women [84, 85].
The majority of sarcopenia research in this area assesses
25-hydroxyvitamin D (25OHD). ALM relative to body
height is significantly lower in older men with low 25OHD
values [41], and the odds of losing more than 3% of muscle
mass over 3 years were around two times greater in
Longitudinal Aging Study Amsterdam (LASA) participants
with low (<25 nmol/L) serum 25OHD levels, compared to
participants with high (>50 nmol/L) levels at baseline [86].
Relative ALM was positively associated with 25OHD in
cross-sectional analyses in TASOAC, although not in
longitudinal analyses [87]. Higher 25OHD levels have
been also associated with decreased body sway [88] and
improved balance [89], and this may partly explain the
association of vitamin D with reduced falls, in older adults
[90–92]. High levels of 25OHD are also associated with
better performance in assessments of frailty [69, 93] and
independence [94], gait speed [89], stair climbing ability
[90], walking ability and sit-to-stand tests [95], and the
Short Physical Performance Battery [96].
Whether vitamin D-associated improvements in physical
performance in older adults can be attributed to increased
skeletal muscle function is unclear. In a cross-sectional
analysis of the Osteoporosis Prospective Risk Assessment
study, positive associations were observed between 25OHD
and thigh strength in women aged 75 years [89], and
25OHD was positively associated with knee and arm
extension strength in Italian women aged 68–75 years
[97]. Also, 25OHD was positively associated with hand
grip strength in the InCHIANTI study [96], and in an
examination of Norwegian older adults [90]. Cross-
sectional analyses from an Australian population-based
study demonstrated that participants with insufficient
25OHD had lower leg strength and muscle quality
compared to those with normal 25OHD [87]. In contrast,
a study of women with osteoporosis demonstrated no
association between low 25OHD and trunk muscle strength
[88], and in randomised samples of French older women no
significant associations were observed for 25OHD with
quadriceps or hand grip strength [98, 99].
Prospective studies suggest vitamin D may be important
for muscle function, however. A 3-year follow-up analysis
in the WHAS reported that women classified across varying
25OHD levels had similar changes in lower and upper
extremity strength, and physical function [100], but women
in the lowest quartile of 25OHD at baseline had around a
30% increased risk of developing frailty [70]. Also, in the
LASA, the odds for a loss of grip strength greater than 40%
over 3 years were around two times greater for participants
with low serum 25OHD levels, than for those with high
25OHD at baseline [86], and in longitudinal analyses of
TASOAC, baseline 25OHD was a positive predictor of
change in leg strength and muscle quality after adjustment
for physical activity, sun exposure and season of blood
sampling [87]. It appears that vitamin D may therefore play
an important role in the maintenance of muscle function for
older adults.
2.4 Chronic disease
Chronic disorders are highly prevalent in older adults [101],
and declines in skeletal muscle mass and function may be
an additional comorbid outcome of chronic disease. It has
recently been suggested that skeletal muscle wasting
directly attributable to chronic disease should be termed
“myopenia”, with sarcopenia referring only to muscle
declines associated with ageing [102]. However, a consen-
sus is yet to be reached on this debate or the appropriate
terminology, and so the following section examines chronic
disease as a potential predictor of sarcopenia, rather than of
myopenia.
Men with low muscle mass are significantly more likely
to report lung and cardiovascular disease [40, 44], and
chronic lung disease and atherosclerosis are also associated
with low height-adjusted ALM [103]. Although stroke-
associated disability is usually attributed to brain injury, the
disability is also associated with muscle atrophy and
neuromuscular changes [104]. Lean mass has been shown
to be reduced in older adults with early Alzheimer’s disease
[105], and poor psychological health also predicted a
steeper decline in hand grip strength over 4 years in a
population-based study of UK older adults [14]. Moreover,
in older Japanese-American men, a steeper decline in grip
strength after around 27 years was associated with
prevalent stroke, diabetes, arthritis, coronary heart disease
and chronic obstructive pulmonary disease [15].
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interrelated and common genetic factors may influence age-
related skeletal muscle and bone changes [106]. Also,
mechanical influences, particularly skeletal muscle strength,
influence the control of bone loss during ageing [107]. In
concert with the association between chronic disease and
sarcopenia, this raises the potential of a synergistic
relationship between muscle and skeletal components in
which age-related bone disorders influence the develop-
ment and progression of sarcopenia in older adults.
Osteoarthritis (OA) represents a group of diseases which
affect all components of the joints and results in symptoms
including joint pain, tenderness and movement restriction
[108]. OA prevalence increases markedly with age [109]
and is a major cause of disability in older adults [110], and
such disability may in part be explained by OA influences
on declines in skeletal muscle function.
Older men with hip OA have significantly lower CSA of
the thigh and pelvic muscles on the most severely affected
hip compared to the opposite hip [111], and older women
with knee OA have reduced lower limb lean mass
compared to age- and sex-matched controls [112]. Research
has demonstrated that reduced knee extension strength is a
correlate of self-reported knee pain [113], and isometric
quadriceps strength was lower for older adults with knee
pain compared to those without, partly due to reduced
muscle activation [114]. Also, increased odds of falling
have been reported for older adults with self-reported OA
[115].
It has been reported that quadriceps weakness may be
present in patients demonstrating knee radiographic OA
(ROA) but not reporting pain [116], suggesting that the
early structural changes associated with OA may also be
predictive of sarcopenia progression. Men with hip OA
have demonstrated lower strength of the hip muscles
compared to controls [111], and knee ROA has also been
associated with increased self-reported stair climbing and
walking disability [117]. However, in Chinese older adults,
the significant association between quadriceps weakness
and knee ROA was mediated by pain [118].
This finding is supported by the only prospective
analyses we are aware of. In 480 adults over the age of
65, baseline knee ROA predicted a significant decline in
performance of a stair climbing task over 30 months [119],
although the investigators reported that the association was
mediated by knee pain intensity and knee strength.
Similarly, baseline knee pain (but not ROA) predicted a
greater decline in leg strength and muscle quality, as well as
a greater increase in objectively measured falls risk over
almost 3 years, although these associations were observed
for women only [120]. Thus, it is possible that OA and
other age-related disorders exacerbate sarcopenia progres-
sion in older adults as a result of avoidance of activity due
to the pain experience and effective management of chronic
disease and pain may represent an important target for
sarcopenia prevention.
2.5 Medication use
Prevalence of prescription medication usage may be as high
as 80% in community-dwelling older adults [121]. An
increase in medication use over 10 years is associated with
greater decline in knee strength in older men [13]. Hand
grip strength significantly decreases [122], and self-
reported falls increase, with higher self-reported medication
use in older adults [123]. Older adults receiving hypnotics
and antidepressants may in particular be at an increased risk
for falling and disability [124]. Hypnotics, anxiolytics and
antidepressants have been associated with increased odds of
falls in British older women [125], and benzodiazepines
have also been shown to be related to incident mobility and
ADL disability [126]. A 1-year prospective study of
Australian older women lends weight to the argument that
such outcomes may be related to skeletal muscle function
decline; in this study, the use of benzodiazepines and
antidepressants was significantly associated with multiple
falls and impaired lower limb muscle strength [127].
Cardiovascular medications may also influence skeletal
muscle changes in older adults. Angiotensin-converting
enzyme (ACE) inhibitors may be preventative of functional
declines through improvements in the fatigability of the
skeletal muscle [128], and in the WHAS, women who
reported continued use of ACE inhibitors demonstrated
lower declines in knee extensor strength and walking speed
over 3 years compared to intermittent and non-users [129].
A cross-sectional analysis of the HCS, however, observed
that while cardiovascular drugs, including furosemide,
nitrates, calcium channel blockers and fibrates were
associated with decreased hand grip strength, no associa-
tions were observed for ACE inhibitors [122].
Statins (or HMG-CoA reductase inhibitors) are the most
widely used prescription medication [130] due to their
protective effects for coronary events and total mortality
[131]. Statins have relatively few side effects; the most
common being myopathy including muscle pain, although
rhabdomyolysis occurs in rare cases [132–134]. The
mechanisms by which statin use may cause myopathy are
unclear; however, pathways may include reductions in the
production of sarcolemmal and sarcoplasmic reticular
cholesterol, ubiquinones and coenzyme Q10 or isoprenoids
and regulatory proteins [135, 136].
However, in a 1-year study of over 750 older adults,
statin users actually demonstrated significantly better
performance in a chair stand test than non-users [137].
Similarly, in adults with and without peripheral arterial
disease (PAD), statin users demonstrated improved perfor-
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and amongst PAD patients statin use was again associated
with improved performance in these tests after 3 years
[139]. However, the incidence of frailty development was
similar between statin users and controls after 3 years in US
older women [140], and in the HCS, no associations were
observed between statin use and hand grip strength [122].
High dose statin supplementation for older adults has
resulted in no declines in aerobic or skeletal muscle
performance [141].
Nevertheless, statin users may demonstrate increased
muscle damage in response to exercise [142], and in a small
clinical trial, patients were able to repeatedly distinguish
periods of statin use from placebo use, and hip muscle
strength tests demonstrated weakness during statin therapy.
Skeletal muscle biopsies also indicated mitochondrial
dysfunction which was reversed during subsequent placebo
use [143]. Moreover, statin users in a 3-year study of older
adults demonstrated greater decreases in leg strength and
muscle quality, and a greater increase in falls risk than non-
users, and this effect was reversed for those who reported
cessation of statin use during the follow-up period [144].
Research to date is yet to clarify whether statin therapy
contributes to functional decline; however, it is possible that
older adults receiving some forms of pharmacotherapy are
more at risk of disability due to increased rates of
sarcopenia progression.
3 Summary
This review demonstrates that a number of modifiable
lifestyle-related factors may be associated with skeletal
muscle mass and function changes, but further prospective
population-based studies are required to confirm these
associations and examine other potential lifestyle behaviours
which may contribute to sarcopenia.
Nevertheless, whilst factors that contribute to sarcopenia
such as age-related body composition, inflammatory,
metabolic and endocrine changes may be inevitable; a
focus on improving lifestyle behaviours and overall health
of older adults may represent the most effective means of
reducing the impact of sarcopenia. Intervention studies will
be important in demonstrating the potential for older adults
to adopt and maintain lifestyle changes, as well as the
magnitude of skeletal muscle mass and functional improve-
ments that may be associated with these behaviours. In
order to effectively design and implement interventions
though, it is vital that practitioner and public awareness is
increased and that consensus is achieved on the clinical
definition of sarcopenia [145].
Such studies may include trialling of health promotion
techniques to encourage adequate general activity and
nutrient intake in community-dwelling older adults, inves-
tigation of vitamin D supplementation as a therapeutic
intervention for sarcopenia progression, investigation of
effective pain control techniques and strengthening exer-
cises for OA patients, and randomised–controlled trials to
clarify the functional impact of statin use in older adults.
Sarcopenia is associated with a reduced ability to
complete everyday tasks and an increased risk of falls,
both of which may result in loss of independence in older
adults. As western populations age, the social and economic
burden associated with sarcopenia will increase. It is
important that future studies continue to investigate both
the aetiology of sarcopenia and its potential treatments, and
promote these effectively to other researchers, practitioners
and older adults themselves.
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